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The primary structure of a human pancreastatin-like peptide was determined from a pancreatic glucagonoma. The 28- 
amino acid peptide was identified using a specific antibody raised against porcine pancreastatin 149 and showed a 75% 
sequence homology with porcine pancreastatin 2249 and bovine chromogranin A 267-294. Several forms of pancrea- 
statin-like immunoreactivity were found in human endocrine tumors of which the purified peptide was the smallest and 
contained the active sequence of pancreastatin. 
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1. INTRODUCTION 
Pancreastatin is a 49-amino acid C-terminal 
amidated peptide recently isolated from porcine 
pancreas by Tatemoto et al. [I], which has been 
shown to inhibit glucose-stimulated insulin release 
[ 11. The reported bioactivity of this peptide sug- 
gests that its presence in man could have potential 
importance in normal and pathological states such 
as diabetes mellitus. A striking structural similarity 
between porcine pancreastatin and a part of bovine 
chromogranin A 267-294 has led to the suggestion 
that chromogranin A is a precursor protein of pan- 
creastatin [2,3]. A sensitive RIA system has been 
developed using a specific antibody raised against 
porcine pancreastatin l-49. Using this RIA, we 
detected PS-LI in a large number of human 
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neuroendocrine tumors. The high concentration of 
PS-LI in a pancreatic glucagonoma has enabled us 
to analyse and purify the human peptide. 
2. MATERIALS AND METHODS 
2.1. Tumor 
The pancreatic glucagonoma was obtained about 4 h 
postmortem from a 55year-old female patient who had been 
definitively diagnosed by a combination of clinical and 
radiological features, a specific hormone assay which showed 
plasma glucagon levels >2000 pmol/l, and elevated blood 
sugar of 200-800 mg/dl. Immediately after removal, the tumor 
(about 200 g wet wt) was snap-frozen in liquid nitrogen and 
stored at - 70°C for subsequent peptide extraction. 
2.2. Extraction 
The tumor was homogenized and extracted in 550 ml of 
0.5 M acetic acid with 0.1% DDT (Sigma, St Louis, USA) for 
15 min at 100°C. 
2.3. Radioimmunoassay 
Antisera were raised in adult rabbits immunised with syn- 
thetic porcine pancreastatin l-49 amide (Peninsula, CA, USA) 
conjugated to BSA with glutaraldehyde [4]. One rabbit (YN4) 
produced a highly sensitive antiserum which was used for RIA 
at a final dilution of I : 8OOCO. Synthetic Tyr”-pancreastatin 
l-49 was iodinated by chloramine-T oxidation 151. The 
iodinated product was purified by using HPLC. The assay was 
carried out in 0.8 ml of 60 mM phosphate buffer, pH 7.4, con- 
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taining 10 mM EDTA, 8 mM sodium azide and 0.3% BSA. 
After addition of antibody and labelled peptide (300 
count/l0 s), the assay was incubated for 4 days at 4’C. The 
assay had 100% cross-reactivity with the pancreastatin frag- 
ment 33-49 and negligible cross-reactivity (<0.02%) with 
human insulin, glucagon, somatostatin, pancreatic polypeptide, 
arginine-vasopressin and gastrin. 
2.4. Purification 
After centrifugation (8000 rpm) of the tissue extract for 
30 min and filtration, the supernatant was adsorbed onto Sep- 
Pak Cl8 cartridge (Waters, USA) which had been previously 
equilibrated in aqueous 0.1% TFA. After removal of unadsorb- 
ed material by washing with water, the adsorbed peptides were 
eluted using 0.1% TFA in 60% ACN. The eluted sample was 
lyophilized and loaded onto a Sephadex G-50 superfine gel col- 
umn (1.5 x 100 cm, Pharmacia, Sweden) and eluted with 0.1 M 
acetic acid at a flow rate 3.2 ml/h and 1.6 ml fractions were col- 
lected. The PS-LI peak of K,, 0.40 (fig.1) was lyophilized, 
reconstituted with 0.1% TFA in water and subjected to reverse- 
phase FPLC on a PepRPC column (C18, Pharmacia) with a 
gradient from 0 to 45% solvent B (solvent A: 0.1070 TFA in 
water; solvent B: 0.1% TFA in ACN) over 60 min at a flow rate 
of 1 ml/min, and 1 ml fractions were collected for subsequent 
assay of PS-LI. One major PS-LI peak was found at 20% 
ACN. The peak was reloaded twice on the same column with 
more shallow gradients IO-35% (2nd run) and 15-25% (3rd 
run) solvent B over 60 min. The PS-LI peak of the 3rd run was 
then subjected to FPLC ion-exchange system on a Mono Q col- 
umn (Pharmacia) with a gradient from 0 to 100% solvent B 
[solvent A: 0.08 M Tris buffer, pH 9.2 (BDH Chemicals, 
England); solvent B: solvent A in 1 M NaCI] over 60 min at a 
flow rate of 0.5 ml/min (4th run), and 1 ml fractions were col- 
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Fig. 1. Sephadex G-50 gel permeation profile of PS-LI in extract 
of the tumor. The column was calibrated with dextran blue 
(V,), horse heart cytochrome c (CC), and Natz51 (VJ as 
molecular size markers. Arrow P indicates the eluted position 
of porcine pancreastatin. The concentrations of PS-LI are 
expressed as femtomole per fraction. 
Fig.2. Final purification of human pancreastatin fragment from 
glucagonoma. Profile: 210 nm UV absorbance. Closed column: 
PS-LI. Sample: PS-LI fractions of FPLC 5th run at 36-37 min. 
Flow rate: 1.0 ml/min. Column: 219TP54 peptide & protein 
diphenyl column (4.6 x 250 mm, Vydac). Solvent: 
HzO/ACN/lO% TFA = (A) 90:10:1, (B) 40:60:1 (v/v). 
Linear gradient elution from (A) to (B) for 120 min (---). 
lected for subsequent assay. The peak of PS-LI was subjected 
again to FPLC on a PepRPC column under the same conditions 
as the 3rd run (5th run). The peptide was found to be only 40% 
pure and hence the lyophilized PS-LI material was further sub- 
jected to reverse-phase HPLC on a 219TP54 peptide & protein 
diphenyl column (4.6 x 250 mm, Vydac, CA, USA) at a flow 
rate of 1 ml/min with a linear gradient elution from 10 to 60% 
ACN in 0.1070 TFA over 120 min at ambient temperature (the 
last run). Column effluents from HPLC were monitored by 
measuring absorbance at 210 nm and 280 nm. 
2.5. Sequence analyses 
Sequence analysis was performed mainly by a gas-phase se- 
quencer (model 47OA, Applied Biosystems) using about 
Table 1 
Amino acid composition of human pancreastatin fragment 
Amino acid 
Ser 0.88 (1) 
Glu 11.29 (11) 
Pro 1.91 (2) 
Gly 4.11 (4) 
Ala 1.07 (1) 
Val 1.77 (2) 
Met 0.78 (1) 
Leu 1.06 (1) 
Phe 0.92 (1) 
LYS 2.05 (2) 
His 0.96 (1) 
Arg 0.99 (1) 
Total (28) 
Numbers in parentheses represent he nearest integers 
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Fig.3. Yield of PTH-amino acid liberated at each cycle of 
Edman degradation. One letter notation for amino acids was 
used. 
270 pmol of the peptide (61. The resulting PTH-amino acids 
were analyzed by reverse-phase HPLC (model 120A, Applied 
Biosystems) concerted with a gas-phase sequencer. PTH-amino 
acids are measurable in quantities as low as 1 pmol. Amino acid 
analysis was carried out with Hitachi-835 amino acid analyzer, 
after acid hydrolysis of the peptide (-360 pmol) in 6 M HCI 
containing 0.1% phenol and 0.02% 2-mercaptoethanol at 
110°C for 24 h. The C-terminal amino acid was determined by 
the method of Tatemoto and Mutt 171; purified peptide was 
digested in 50 mM Hepes buffer (pH 7.55) with 1 pg of TPCK- 
trypsin at 37°C for 2 h and the glycine amide generated was 
identified as its dansyl (N,N-dimethylaminonaphthylsulfonyl) 
derivative on a polyamide sheet. 
3. RESULTS 
Fig.1 shows the gel-permeation profile of the 
original tumor extract. Three major PS-LI peaks 
(K,, 0.04,O. 18 and 0.40) were found, and the peak 
at K,, 0.4 was used for purification because it was 
the nearest to porcine pancreastatin at K,, 0.33. 
Fig.2 shows the final HPLC purification profiles. 
A portion of the isolated peptide was hydrolyzed 
and analyzed for its amino acid composition. As 
summarized in table 1, this peptide consisted of 28 
amino acid residues. Although 21 amino acids 
shorter than pig pancreastatin, this peptide has an 
amino acid composition similar to the C-terminal 
1 5 10 
half of porcine pancreastatin. Based on the amino 
acid analysis data, 2.10 nmol was purified from 
200 g of human glucagonoma. 
Amino acid sequence analysis was performed by 
a gas-phase sequencer and the PTH-amino acid 
liberated at each cycle of Edman degradation was 
successfully identified up to the C-terminal 
residue, as shown in fig.3. C-terminal Gly-NH2 
was also clearly identified as its dansylated 
derivative by the method of Tatemoto and Mutt 
(not shown). Thus, the amino acid sequence of the 
peptide was established, as shown in fig.4, and this 
peptide was found to correspond to the C-terminal 
subsequence 22-49 of porcine pancreastatin. 
4. DISCUSSION 
Human pancreastatin l-28 amide differs in only 
seven amino acids from porcine pancreastatin 
22-49 and bovine chromogranin A 267-294. 
Moreover, a single point mutation in each codon 
could have caused the change in each of the dif- 
ferent amino acids between human pancreastatin 
and porcine pancreastatin 22-49, and 6 of the 7 
amino acids in bovine chromogranin A 267-294. 
This is consistent with a common evolutionary 
origin of the genes for chromogranin A/pan- 
creastatin of different species. The two larger 
molecular forms of PS-LI identified by gel 
chromatographic analysis are possibly large 
molecular mass precursor proteins, consistent with 
the hypothesis that pancreastatin is processed from 
a precursor such as chromogranin A. 
The amino acid sequence of human pan- 
creastatin is 21 amino acids shorter than porcine 
pancreastatin. For the human pancreastatin to be 
processed from a larger molecule would involve a 
split between two proline residues if the sequence 
of the large human form was similar to porcine 
pancreastatin. Such a processing is unusual, 
because X-Pro bond is usually resistant to pro- 
teolytic digestion [9]. Although we do not have any 
structural information of the N-terminal sequence 
15 20 25 
(a); PEGKGEQEHSQQKEEEEMAVVPQGLFRG-NH2 
(b); P E G K G A*R*E H S R*Q E*E E E E T*A G*A*P Q G L F R G-NH2 
(c); P E G K G E W*A*H S R*Q E*E E E - M A R*A*P Q V*L F R G 
Fig.4. Amino acid sequences of human pancreastatin fragment (a), porcine pancreastatin 22-49 (b) and bovine chromogranin A 
267-294 (c). (*) Different amino acid from human pancreastatin. One letter notation for amino acids was used. 
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in complete human pancreastatin, X residue of X- 
Pro structure might be aspartic acid, since Asp-Pro 
bond is easily cleaved in acetic acid solution at high 
temperature. On the other hand, the C-terminal 
heptapeptide amide, which is essential to exert 
biological activity [lo], is completely conserved in 
both human and porcine pancreastatin. In recent 
years, chromogranin A has emerged as a potential 
universal marker for neuroendocrine tissues and 
tumors [l l-151. If human chromogranin A is a 
precursor protein of pancreastatin, neuroen- 
docrine tumors could produce pancreastatin and 
thus possibly cause hyperglycemia. Further in- 
vestigations are needed to clarify the biological 
role of this new peptide. 
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